BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng J, Wang L, Ni J, Beretov J, Wasinger V, Wu D, Duan W, Graham P, Li Y. Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Review of Proteomics 2016;13:905-15. [DOI: 10.1080/14789450.2016.1233065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Alharbi M, Sharma S, Guanzon D, Lai A, Zuñiga F, Shiddiky MJA, Yamauchi Y, Salas-Burgos A, He Y, Pejovic T, Winters C, Morgan T, Perrin L, Hooper JD, Salomon C. miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer. Nanomedicine 2020;28:102207. [PMID: 32334098 DOI: 10.1016/j.nano.2020.102207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
2 Swiatly A, Plewa S, Matysiak J, Kokot ZJ. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. J Ovarian Res 2018;11:88. [PMID: 30270814 DOI: 10.1186/s13048-018-0460-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
3 Huang R, Chen Z, He L, He N, Xi Z, Li Z, Deng Y, Zeng X. Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application. Theranostics 2017;7:3559-72. [PMID: 28912895 DOI: 10.7150/thno.20797] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
4 El Bairi K, Amrani M, Kandhro AH, Afqir S. Prediction of therapy response in ovarian cancer: Where are we now? Critical Reviews in Clinical Laboratory Sciences 2017;54:233-66. [DOI: 10.1080/10408363.2017.1313190] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]